Novartis Releases Prexige; New Data Confirm That Prexige (lumiracoxib) is Effective in Relieving Symptoms of Osteoarthritis

| Source: Novartis Novartis

BASEL, Switzerland, June 20, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS)(Other OTC:NVSEF):

Data from key clinical Phase III studies presented for the first time at EULAR, the European League Against Rheumatism annual congress in Lisbon, demonstrate that Prexige(R) (lumiracoxib), a novel COX-2 selective inhibitor, provides effective relief of the symptoms of osteoarthritis (OA).

Please see full press release under the following link: http://reports.huginonline.com/908606/119660.pdf 



            








        

            

                

                    
Tags

                            
                                PHARMACEUTICALS
                            
                            
                                PRODUCT
                            

                



        




    

        

        
Contact Data